# Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

> **NCT05283356** · PHASE4 · UNKNOWN · sponsor: **Fundacin Biomedica Galicia Sur** · enrollment: 1206 (estimated)

## Conditions studied

- Severe Aortic Valve Stenosis
- Aortic Valve Stenosis
- Transcatheter Aortic Valve Replacement (TAVR)
- Transcatheter Aortic Valve Implantation (TAVI)

## Interventions

- **DRUG:** Ticagrelor 60mg

## Key facts

- **NCT ID:** NCT05283356
- **Lead sponsor:** Fundacin Biomedica Galicia Sur
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-21
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 1206 (ESTIMATED)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283356, "Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05283356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*